Interplay of parathyroid hormone and aldosterone antagonist in prevention of heart failure hospitalizations in chronic kidney disease
Open accessAbstract
Background: Aldosterone antagonists may mediate their effects on heart failure through parathyroid hormone (PTH) in chronic kidney disease (CKD) patients. Methods: Patients with CKD on spironolactone were selected and matched for age, gender, race, use of a vitamin D analogue, the number of antihypertensive medications, and CKD stage. PTH levels before and after the first prescription of spironolactone were measured. A thorough chart review was conducted to assess for heart failure hospitalizations. An adjusted Cox proportional model was used to calculate the hazard ratio (HR) for heart failure hospitalizations among cases versus controls. Results: There were a total of 950 (mean age 67±13 years, 40% men) patients with CKD. Of these, there were 48 hospitalizations for heart failure among the cases and 82 among the controls (HR 0.37; 95% confidence interval (CI) 0.19–0.74, p =0.005). We noted a more significant decrease in PTH levels among the cases when compared to the controls ( p <0.0001). The adjusted hazard for heart failure hospitalization increased with higher PTH levels ( p =0.002) and mediation analysis revealed change in PTH level as a significant mediator of heart failure hospitalization ( p =0.04). Conclusion: Aldosterone antagonists may be helpful in preventing hospitalizations for heart failure exacerbation in CKD patients through a PTH-mediated effect.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603 · see citing works
Heidenreich, P. A., Trogdon, J. G., Khavjou, O. A., Butler, J., Dracup, K., Ezekowitz, M. D., Finkelstein, E. A., Hong, Y., Johnston, S. C., Khera, A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820a55f5 · Cited by 3,208 · see citing works
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
Massry, S. G., Coburn, J. W., Chertow, G. M., Hruska, K. A., Langman, C. B., Malluche, H. H., Martin, K. J., McCann, L. M., McCarthy, J. T., Moe, S. M., et al. (2003) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 2,527 · see citing works
Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure
Hamdy, N. A. T., Kanis, J. A., Beneton, M. N. C., et al. (1995) · BMJ · doi:10.1136/bmj.310.6976.358 · Cited by 323 · see citing works
Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease: An Overview
Bailie, G. R., & Massry, S. G. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.12.1687 · Cited by 252 · see citing works
Hyperparathyroidism and the Calcium Paradox of Aldosteronism
Chhokar, V. S., Sun, Y., Bhattacharya, S. K., Ahokas, R. A., Myers, L. K., Xing, Z., Smith, R. A., Gerling, I., & Weber, K. T. (2005) · Circulation · doi:10.1161/01.cir.0000155621.10213.06 · Cited by 208 · see citing works
Renal Dysfunction in Patients With Heart Failure With Preserved Versus Reduced Ejection Fraction
McAlister, F. A., Ezekowitz, J. A., Tarantini, L., Squire, I. B., Michel Komajda, N., Bayés‐Genís, A., Gotsman, I., WHALLEY, G. A., Earle, N. J., Poppe, K., et al. (2012) · Circulation Heart Failure · doi:10.1161/circheartfailure.111.966242 · Cited by 202 · see citing works
Jaarsma, T., van der Wal, M. H. L., Hogenhuis, J., Lesman, I., Luttik, M. L. A., Veeger, N. J. G. M., & van Veldhuisen, D. J. (2003) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2003.09.010 · Cited by 187 · see citing works
Chronic Kidney Disease and Outcomes in Heart Failure With Preserved Versus Reduced Ejection Fraction
Smith, D. H., Thorp, M. L., Gurwitz, J. H., McManus, D. D., Goldberg, R. J., Allen, L. A., Hsu, G., Sung, S. H., Magid, D. J., & Go, A. S. (2013) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000221 · Cited by 169 · see citing works
Tomaschitz, A., Ritz, E., Pieske, B. M., Rus-Machan, J., Kienreich, K., Verheyen, N., Gaksch, M., Grübler, M. R., Fahrleitner‐Pammer, A., Mrak, P., et al. (2013) · Metabolism · doi:10.1016/j.metabol.2013.08.016 · Cited by 167 · see citing works
Schierbeck, L. L., Jensen, T. S., Bang, U. C., Jensen, G. B., Køber, L., & Jensen, J. B. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfr016 · Cited by 146 · see citing works
Aldosterone in Chronic Kidney and Cardiac Disease
Hostetter, T. H., & Ibrahim, H. N. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000086472.65806.73 · Cited by 137 · see citing works
Poor Outcome in End-Stage Heart Failure Patients with Low Circulating Calcitriol Levels
Zittermann, A., Schleithoff, S. S., Götting, C., Dronow, O., Fuchs, U., Kühn, J., Kleesiek, K., Tenderich, G., & Köerfer, R. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.01.013 · Cited by 129 · see citing works
Pilz, S., Kienreich, K., Drechsler, C., Ritz, E., Fahrleitner-Pammer, A., Gaksch, M., Meinitzer, A., März, W., Pieber, T. R., & Tomaschitz, A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2183 · Cited by 118 · see citing works
Plasma Parathyroid Hormone and Risk of Congestive Heart Failure in the Community
Hagström, E., Ingelsson, E., Sundström, J., Hellman, P., Larsson, T. E., Berglund, L., Melhus, H., Held, C., Michaëlsson, K., Lind, L., et al. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq134 · Cited by 113 · see citing works
Ohtani, T., Ohta, M., Yamamoto, K., Mano, T., Sakata, Y., Nishio, M., Takeda, Y., Yoshida, J., Miwa, T., Okamoto, M., et al. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00402.2006 · Cited by 104 · see citing works
Brown, J. M., Williams, J. S., Luther, J. M., Garg, R., Garza, A. E., Pojoga, L. H., Ruan, D. T., Williams, G. H., Adler, G. K., & Vaidya, A. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.01910 · Cited by 88 · see citing works
Serum intact parathyroid hormone levels predict hospitalisation for heart failure
Sugimoto, T., Tanigawa, T., Onishi, K., et al. (2008) · Heart · doi:10.1136/hrt.2008.147652 · Cited by 75 · see citing works
Edwards, N. C., Steeds, R. P., Chue, C. D., Stewart, P. M., Ferro, C. J., & Townend, J. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04102.x · Cited by 73 · see citing works
Aldosterone antagonism in chronic kidney disease.
Ponda, M. P., & Hostetter, T. (2006) · American Society of Nephrology. Clinical Journal · doi:10.2215/cjn.00120106 · Cited by 70 · see citing works
Laguardia, S. P., Dockery, B. K., Nelson, M. D., Weber, K. T., Bhattacharya, S. K., & Carbone, L. D. (2006) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200609000-00003 · Cited by 68 · see citing works
Secondary Hyperparathyroidism in Patients with Untreated and Treated Congestive Heart Failure
Khouzam, R. N., Weber, K. T., Flax, S. D., Dishmon, D. A., Farah, V., & Carbone, L. D. (2006) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200601000-00009 · Cited by 54 · see citing works
Relation of Serum Parathyroid Hormone Level to Severity of Heart Failure
Altay, H., Zorlu, A., Binici, S., Bilgi, M., Yılmaz, M. B., Çölkesen, Y., Erol, T., & Müderrisoğlu, H. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.08.039 · Cited by 51 · see citing works
Patel, K., Fonarow, G. C., Kitzman, D. W., Aban, I., Love, T. E., Allman, R. M., Gheorghiade, M., & Ahmed, A. (2013) · JACC Heart Failure · doi:10.1016/j.jchf.2012.08.001 · Cited by 44 · see citing works
Biermann, J., Neumann, T., Angermann, C. E., Erbel, R. M., Maisch, B., Pittrow, D. B., Regitz‐Zagrosek, V., Scheffold, T., Wachter, R., Gelbrich, G., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.01.099 · Cited by 43 · see citing works
Loncar, G., Nedeljković, B. B., Dimković, S., Prodanović, N., Radojicic, Z. A., Čvorović, V., Putniković, B., & POPOVIC, V. M. (2010) · Journal of Endocrinological Investigation · doi:10.1007/bf03347080 · Cited by 36 · see citing works
Sim, J. J., Shi, J. M., Calara, F. B., Rasgon, S. A., Jacobsen, S., & Kalantar‐Zadeh, K. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834bbc8a · Cited by 31 · see citing works
Khalid, F., Qureshi, W., Qureshi, S., Alirhayim, Z., Garikapati, K., & Patsias, I. (2013) · Renal Failure · doi:10.3109/0886022x.2013.819766 · Cited by 28 · see citing works
Self-citationParathyroid Hormone and Heart Failure: Novel Biomarker Strategy
Altay, H., & Çölkesen, Y. (2013) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530311313010012 · Cited by 23 · see citing works
Heshka, J., Ruzicka, M., Hiremath, S. S., & McCormick, B. B. (2010) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2010.09.006 · Cited by 23 · see citing works
Arenas, M. D., Álvarez-Ude, F., Torregrosa, J., et al. (2008) · PubMed · Cited by 20 · see citing works
Sugimoto, T., Dohi, K., Onishi, K., et al. (2012) · Heart · doi:10.1136/heartjnl-2012-302779 · Cited by 19 · see citing works
Interplay Between Sodium and Calcium Regulatory Hormones
Tomaschitz, A., & Pilz, S. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.02253 · Cited by 18 · see citing works
Gruson, D., Lepoutre, T., Ahn, S. A., et al. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.12.002 · Cited by 10 · see citing works
Portadores de CDI com limiar de desfibrilação elevado: evolução clínica e alternativas terapêuticas
de Lima, C. E. B., Filho, M. M., Silva, R. T., Tamaki, W. T., de Oliveira, J. C., Martins, D. C., Nishioka, S., Pedrosa, A., de Siqueira, S. F., & Costa, R. (2008) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2008000300004 · Cited by 7 · see citing works
Hiperpotassemia na vigência de espironolactona em pacientes com insuficiência cardíaca descompensada
Lima, M., Ochiai, M. E., Cardoso, J. N., Morgado, P. C., Munhoz, R. T., & Barretto, A. C. P. (2008) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2008001500009 · Cited by 5 · see citing works
Bone mass, vitamin D deficiency and hyperparathyroidism in congestive heart failure.
Díez‐Pérez, A., Nogués, X., Mellibovsky, L., et al. (1998) · PubMed · Cited by 3 · see citing works
Aldosterone Inhibition in Patients With Heart Failure With Preserved Ejection Fraction
Neil, C., Singh, S., & Frenneaux, M. P. (2013) · JAMA · doi:10.1001/jama.2013.7970 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The renin–angiotensin–aldosterone system and calcium-regulatory hormones
Vaidya, A., Brown, J. M., & Williams, J. S. (2015) · Journal of Human Hypertension · doi:10.1038/jhh.2014.125 · Cited by 93 · see citing works
Interrelated aldosterone and parathyroid hormone mutually modify cardiovascular mortality risk
Tomaschitz, A., Pilz, S., Rus-Machan, J., Meinitzer, A., Brandenburg, V. M., Scharnagl, H., Kapl, M., Grammer, T., Ritz, E., Horina, J. H., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.062 · Cited by 27 · see citing works
Dobreva, E. A., Bibik, E. E., Eremkina, A. K., Ajnetdinova, A. R., Nikankina, L. V., Malysheva, N. M., & Mokrysheva, N. G. (2020) · Terapevticheskii Arkhiv · doi:10.26442/00403660.2020.10.000725 · Cited by 4 · see citing works
“АТ II, пг/мл 38 [30; 42,2] 25 [17,7; 33,2] 0,032 25,64 [20,14; 35,44] 0,0401 0,8002”
- Authors
- Hassan, M., Qureshi, W., Sroujieh, L. S., Albashaireh, D., BouMalham, S., Liroff, M., Amjad, W., Khalid, F., Hadid, H., & Alirhayim, Z.
- Affiliations
- Wayne State University (US)
- Wake Forest University Health Sciences (US)
- Allama Iqbal Medical College (PK)
- University of Kansas Medical Center (US)
- Venue
- Journal of the Renin-Angiotensin-Aldosterone System
- Publisher
- SAGE Publications
- Published
- 2014-09
- Volume
- 15
- Issue
- 3
- Pages
- 278-285
- ISSN
- 1470-3203 (ISSN-L)
- 1752-8976
- OpenAlex
- W2135782420
- Cited by
- 15
- References
- 38
- Citations by year
- 2023: 1 · 2022: 2 · 2020: 3 · 2019: 1 · 2018: 3 · 2017: 1 · 2016: 2 · 2015: 2
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of the Renin-Angiotensin-Aldosterone System (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Keywords
- parathyroid hormone, mineralocorticoid receptor antagonists, spironolactone, heart failure hospitalization, chronic kidney disease, mediation analysis, vitamin D analogs, mineral and bone disorder
- MeSH terms
- Aged, Aldosterone, Mineralocorticoid Receptor Antagonists, Female, Heart Failure, Hospitalization, Humans, Male, Parathyroid Hormone, Spironolactone, Case-Control Studies, Renal Insufficiency, Chronic, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
